MX2022014907A - Analogos de la hormona paratiroidea para el tratamiento del hipoparatiroidismo. - Google Patents

Analogos de la hormona paratiroidea para el tratamiento del hipoparatiroidismo.

Info

Publication number
MX2022014907A
MX2022014907A MX2022014907A MX2022014907A MX2022014907A MX 2022014907 A MX2022014907 A MX 2022014907A MX 2022014907 A MX2022014907 A MX 2022014907A MX 2022014907 A MX2022014907 A MX 2022014907A MX 2022014907 A MX2022014907 A MX 2022014907A
Authority
MX
Mexico
Prior art keywords
hypoparathyroidism
treatment
parathyroid hormone
pth analogs
novel
Prior art date
Application number
MX2022014907A
Other languages
English (en)
Inventor
Richard D Dimarchi
Fa Zhang
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of MX2022014907A publication Critical patent/MX2022014907A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Se proporciona un derivado novedoso de la hormona paratiroidea que tiene un tiempo de acción prolongado en relación con los péptidos agonistas nativos conocidos de la hormona paratiroidea, al tiempo que minimiza la acción excesiva poco después de la administración. Las composiciones que comprenden los conjugados novedosos de la hormona paratiroidea se pueden usar para tratar el hipoparatiroidismo y la osteoporosis.
MX2022014907A 2020-05-26 2021-05-25 Analogos de la hormona paratiroidea para el tratamiento del hipoparatiroidismo. MX2022014907A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063030004P 2020-05-26 2020-05-26
US202063033586P 2020-06-02 2020-06-02
PCT/US2021/034055 WO2021242756A2 (en) 2020-05-26 2021-05-25 Pth analogs for the treatment of hypoparathyroidism

Publications (1)

Publication Number Publication Date
MX2022014907A true MX2022014907A (es) 2023-01-04

Family

ID=78722812

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014907A MX2022014907A (es) 2020-05-26 2021-05-25 Analogos de la hormona paratiroidea para el tratamiento del hipoparatiroidismo.

Country Status (11)

Country Link
US (1) US20230285578A1 (es)
EP (1) EP4157324A4 (es)
JP (1) JP2023527356A (es)
KR (1) KR20230017844A (es)
CN (1) CN115697380A (es)
AU (1) AU2021278931A1 (es)
BR (1) BR112022024058A2 (es)
CA (1) CA3183120A1 (es)
IL (1) IL298338A (es)
MX (1) MX2022014907A (es)
WO (1) WO2021242756A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4281464A1 (en) 2021-01-20 2023-11-29 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CA3230895A1 (en) 2021-09-22 2023-03-30 Kennett Sprogoe Long-acting pth compound treatments
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434246A (en) * 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
EP1758927A4 (en) * 2004-01-21 2008-09-17 Unigene Lab Inc PARATHYROID HORMONE AMIDE FRAGMENTS AND USES THEREOF
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
AU2009335715B2 (en) * 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2376098A4 (en) * 2008-12-19 2014-06-11 Univ Indiana Res & Tech Corp DIPEPTIDE-LINKED MEDICAL AGENTS
IL238101A (en) * 2015-04-01 2017-01-31 Neodel Tec Ltd Method for making n - noble peptides, polypeptides and proteins
WO2019178462A1 (en) * 2018-03-16 2019-09-19 The General Hospital Corporation Parathyroid hormone polypeptide conjugates and methods of their use
CN110938151B (zh) * 2019-12-30 2023-03-17 重庆艾力彼生物科技有限公司 用于表达甲状旁腺素pth的融合蛋白及重组质粒、重组工程菌

Also Published As

Publication number Publication date
AU2021278931A1 (en) 2022-12-08
CN115697380A (zh) 2023-02-03
IL298338A (en) 2023-01-01
BR112022024058A2 (pt) 2022-12-20
EP4157324A4 (en) 2023-11-22
EP4157324A2 (en) 2023-04-05
WO2021242756A2 (en) 2021-12-02
JP2023527356A (ja) 2023-06-28
US20230285578A1 (en) 2023-09-14
CA3183120A1 (en) 2021-12-02
WO2021242756A3 (en) 2021-12-30
KR20230017844A (ko) 2023-02-06

Similar Documents

Publication Publication Date Title
MX2022014907A (es) Analogos de la hormona paratiroidea para el tratamiento del hipoparatiroidismo.
MX2020007853A (es) Composiciones farmaceuticas para el tratamiento de fibrosis quistica.
MX2023002108A (es) Compuestos como agonistas de glp-1r.
WO2019199861A3 (en) Hemp extract for treatment of pain in animals
PE20210049A1 (es) Composiciones agonistas de gip/glp1
MX2018004192A (es) Formulaciones de análogos de proteína relacionada con la hormona paratiroidea (pthrp), parches transdérmicos de las mismas y usos de las mismas.
ZA202306729B (en) Novel glp-1 analogues
MX2020008387A (es) Usos terapeuticos de agonistas glp1r.
MX2021006969A (es) Ligante peptidico.
MX2020005879A (es) Composiciones administrables vía intravenosa que comprenden ácidos de grado farmacéutico y reguladores del ph, y el uso de las mismas para tratar enfermedades de disfunción mitocondrial, enfermedades metabólicas y de disfunción del modelado de huesos y tejidos.
CL2021003266A1 (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
ECSP23003649A (es) Agonistas del receptor npy2 solubles antecedentes de la invención
CL2022001227A1 (es) Agonistas del receptor npy2
EA201590907A1 (ru) Усиленные полиамином составы для ионтофореза соединения триптана
MX2021002655A (es) Terapia de combinacion para el tratamiento de enfermedad hepatica.
CO2021011025A2 (es) Péptido con acción selectiva hacia receptores gip y glp-2 para el tratamiento contra trastornos óseos
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
MX2023012465A (es) Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea.
MX2021015732A (es) Administracion intranasal de merotocina para mejorar la lactancia.
MX2022013230A (es) Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis.
MX2023000557A (es) Excipientes reductores de la viscosidad y combinaciones de los mismos para formulaciones proteicas altamente concentradas.
BR112022012499A2 (pt) Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo
WO2019094292A8 (en) Compositions and methods of providing thyroid hormone or analogs thereof